Cubist Systematic Strategies’s Kymera Therapeutics KYMR Stock Holding History

Cubist Systematic Strategies’s Portfolio KYMR Stock Details KYMR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	$2.99M	Sell	52,754 -65,998	-56%	-$2.98M	0.01%	1307
2025 Q2	$5.18M	Buy	+118,752	New	+$4.09M	0.02%	1000
2024 Q1	–	Sell	-95,580	Closed	-$2.43M	–	4026
2023 Q4	$2.43M	Buy	+95,580	New	+$1.71M	0.02%	1373
2023 Q1	–	Sell	-99,776	Closed	-$2.49M	–	4185
2022 Q4	$2.49M	Buy	99,776 +83,494	+513%	+$2.23M	0.01%	1669
2022 Q3	$354K	Sell	16,282 -24,010	-60%	-$633K	﹤0.01%	3418
2022 Q2	$793K	Buy	40,292 +26,275	+187%	+$614K	﹤0.01%	2662
2022 Q1	$593K	Buy	+14,017	New	+$592K	0.01%	2423
2021 Q4	–	Sell	-24,962	Closed	-$1.47M	–	3546
2021 Q3	$1.47M	Buy	24,962 +10,883	+77%	+$631K	0.02%	1244
2021 Q2	$683K	Sell	14,079 -10,838	-43%	-$471K	0.01%	1806
2021 Q1	$968K	Buy	+24,917	New	+$1.5M	0.01%	1562

Other funds holding KYMR

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Cubist Systematic Strategies's KYMR Position: Q3 2025 in Review

Cubist Systematic Strategies reduced its Kymera Therapeutics (KYMR) stake by 56% in Q3 2025, selling an estimated $2.98M and leaving 52,754 shares worth $2.99M. The position accounts for 0.01% of the portfolio, ranked #1307.

Cubist Systematic Strategies first reported a position in KYMR in Q1 2021 and has held it in 10 quarters since. The position peaked at $5.18M in Q2 2025. 210 funds tracked by Wall St. Rank hold KYMR as of Q3 2025.

Cubist Systematic Strategies held 52,754 shares of Kymera Therapeutics worth $2.99M as of Q3 2025.
Cubist Systematic Strategies sold 65,998 Kymera Therapeutics shares in Q3 2025, an estimated $2.98M.
Kymera Therapeutics made up 0.01% of Cubist Systematic Strategies's portfolio in Q3 2025, its #1307 holding.
Cubist Systematic Strategies first reported a position in Kymera Therapeutics in Q1 2021 and has held it in 10 quarters since.
Cubist Systematic Strategies's Kymera Therapeutics position peaked at $5.18M in Q2 2025.
210 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q3 2025.

Based on Cubist Systematic Strategies's 13F filing for Q3 2025, filed 14 Nov 2025.